Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Weight-Loss Surgery May Reduce Cancer Risk in People With Type 2 Diabetes
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Stephanie P.
Received at sharesuccess @ ezorbonline.com Friday, November 26, 2021, 01:12 PM PDT
(Unedited)

Dear Folks at Elixir,

Happy holidays! Thank you for everything you've done for me in the past. Thank you for making EZorb and Marvlix available. I love your products, and can't say enough about them!

I wish you and your family a great peaceful holiday season. God bless!

Stephanie

Letter II: From David J.
Received at Testimonial Submit Form Wednesday, November 17, 2021 at 14:49:29
(Unedited)

Hi, my name is Dave Johnson. I started EZorb with 8 caps/day for 3 months, then cut back to 6 caps.

I had shoulder surgery many years ago for calcium deposits and recently developed heel spurs, and the shoulder is kicking up again.

My heart DR asked me how The EZorb was working, as he had given me a one week prescription that had worked for him, (but not for me).

I said these herbals take time to work, but I'm no longer hobbling off to bed from my recliner, and I'm back to walking confidently, leading with my HEELS, so YESS, I believe!

I'm an active 77 yrs young and hope to stay that way.

Our newsletter reaches over 200,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public.

Findings from the prospective Swedish Obese Subjects study suggest that bariatric surgery in people with concomitant type 2 diabetes and obesity is linked to a lower cancer incidence than conventional obesity treatment.

During a median 21.3 years of follow-up, Magdalena Taube (University of Gothenburg, Sweden) and co-authors observed 68 first-time cancer events among 393 participants who underwent bariatric surgery and 74 events among 308 contemporaneously matched controls. This corresponded to incidence rates of 9.1 and 14.1 per 1000 person-years, respectively, and a significant hazard ratio (HR) of 0.63, adjusting for factors such as age, sex, education, and alcohol consumption.

In women, cancer incidence was significantly lower in the surgery versus the control arm, with an adjusted (a)HR of 0.58. Conversely, this association was not observed among men, but there was no significant sex-treatment interaction, the team notes.

Taube et al also found that diabetes remission at 10 years after surgery was associated with a “drastically reduced” risk for cancer development in the overall study population, with an aHR of 0.40.

“Τhis finding supports the role of insulin as a reversible cancer risk factor,” as these individuals “no longer require antidiabetic treatment (including insulin) and have lower endogenous insulin levels,” they write in Diabetes Care.

Original research was published in Diabetes Care 2021; doi:10.2337/dc21-1335.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index